Black Diamond Therapeutics (BDTX) Cash from Investing Activities: 2018-2024
Historic Cash from Investing Activities for Black Diamond Therapeutics (BDTX) over the last 7 years, with Dec 2024 value amounting to $17.0 million.
- Black Diamond Therapeutics' Cash from Investing Activities rose 750.45% to $43.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $130.6 million, marking a year-over-year increase of 146.37%. This contributed to the annual value of $17.0 million for FY2024, which is 3.81% up from last year.
- Black Diamond Therapeutics' Cash from Investing Activities amounted to $17.0 million in FY2024, which was up 3.81% from $16.3 million recorded in FY2023.
- In the past 5 years, Black Diamond Therapeutics' Cash from Investing Activities registered a high of $130.6 million during FY2021, and its lowest value of -$281.7 million during FY2020.
- Its 3-year average for Cash from Investing Activities is $28.9 million, with a median of $17.0 million in 2024.
- Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 1,341,285.71% in 2020, then skyrocketed by 146.37% in 2021.
- Over the past 5 years, Black Diamond Therapeutics' Cash from Investing Activities (Yearly) stood at -$281.7 million in 2020, then spiked by 146.37% to $130.6 million in 2021, then crashed by 59.14% to $53.4 million in 2022, then tumbled by 69.37% to $16.3 million in 2023, then climbed by 3.81% to $17.0 million in 2024.